Condition

Chronic Lymphocytic Leukemia

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 27 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials27

Recruiting3

Common interventions25

Lead sponsors shown15

Clinical trials

27 shown

Evaluation of Skin Tests in Biotherapy AllergiesNCT06971848 · 2026-06-17

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyNCT06151730 · 2024-01-05

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsNCT07474051 · 2026-01-29

ENROLLING_BY_INVITATION

Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)NCT06416267 · 2024-08-01

NOT_YET_RECRUITING

Hypertension and Arrhythmias in CLL Patients Treated With BTK InhibitorsNCT06211413 · 2024-02-07

ENROLLING_BY_INVITATION

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLLNCT05465876 · 2023-10-01

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.NCT05803395 · 2023-09-12

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic LeukemiaNCT05672355 · 2023-08-01

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesNCT05694364 · 2023-01-25

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialNCT05556720 · 2022-12-01

ACTIVE_NOT_RECRUITING

SARS-CoV-2 Donor-Recipient Immunity TransferNCT04666025 · 2020-09-23

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)NCT04716075 · 2019-08-19

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaNCT03096782 · 2017-10-13

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family MembersNCT02194387 · 2014-09-17

ACTIVE_NOT_RECRUITING

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNCT02109224 · 2014-09-01

A Long-term Extension Study of PCI-32765 (Ibrutinib)NCT01804686 · 2013-09-09

ACTIVE_NOT_RECRUITING

Revlimid® as Consolidation Treatment Chronic Lymphocytic LeukemiaNCT01600053 · 2011-11-01

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersNCT01460134 · 2011-10-01

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.NCT01353625 · 2011-04-25

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaNCT01484015 · 2011-02-01

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)NCT00749502 · 2008-09-01

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic LeukemiaNCT00280241 · 2004-06-01

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic LeukemiaNCT00078234 · 2003-11-01

Nonmyeloablative Allogeneic TransplantNCT01272817 · 2001-10-01

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic LeukemiaNCT00021749 · 2001-01-01

Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesNCT00036023

Common interventions

Leading sponsors

City of Hope Medical Center 2 Genta Incorporated 2 M.D. Anderson Cancer Center 2 Abramson Cancer Center at Penn Medicine 1 Alliance for Clinical Trials in Oncology 1 Amgen 1 AvenCell Therapeutics, Inc. 1 Celgene 1 Celldex Therapeutics 1 Gruppo Italiano Malattie EMatologiche dell'Adulto 1 H. Lee Moffitt Cancer Center and Research Institute 1 Janssen Research & Development, LLC 1 Mayo Clinic 1 Monash University 1 National Cancer Institute (NCI) 1

Trial status mix

COMPLETED14

ACTIVE_NOT_RECRUITING3

RECRUITING3

ENROLLING_BY_INVITATION2

TERMINATED2

NOT_YET_RECRUITING1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE29

PHASE18

NA3

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.